Russian drugmakers to get additional subsidies for development of generics

Russian pharmaceutical companies will receive additional subsidies from the state for the development of analogues of foreign drugs, as part of the current state plans for the reduction of import dependence in the country’s pharmaceutical sector, The Pharma Letter’s local correspondent reports.

The planned provision of subsidies has been recently confirmed by Russia’s, Prime Minister Mikhail Mishustin, who noted that "the government will provide additional support to our pharmaceutical manufacturers. They will be able to receive state subsidies for the development and subsequent registration of domestic drugs, analogues of which are now under patent protection.”

Plans for domestic production